通便 发表于 2025-3-25 05:13:38

http://reply.papertrans.cn/15/1438/143703/143703_21.png

instulate 发表于 2025-3-25 09:25:15

http://reply.papertrans.cn/15/1438/143703/143703_22.png

暗讽 发表于 2025-3-25 13:54:00

http://reply.papertrans.cn/15/1438/143703/143703_23.png

绑架 发表于 2025-3-25 19:35:59

Implied Dynamics in the SV-HJM Framework beyond original research hypotheses and the benefit-risk profile of investigational products. The chapter explores this proposition. Admittedly, such task goes beyond a legal inquiry. However, without a detailed understanding of the role of secondary IPD analysis in medical research and drug R&D, a

generic 发表于 2025-3-25 22:57:17

http://reply.papertrans.cn/15/1438/143703/143703_25.png

地壳 发表于 2025-3-26 01:38:56

Asymptotic Combinatorial Coding Theory In view of the allegations of the research-based pharmaceutical companies that mandatory disclosure would ‘impede’ their innovation incentives, it is essential to clarify how IPD disclosure might affect the applicable protection afforded under the existing EU framework. In particular, the analysis

树木心 发表于 2025-3-26 06:54:20

Statistical Mechanics and Number Theory trial data is problematic and how a policy analysis could be conducted. It starts with a brief overview of the basic principles of designing a regulatory intervention and methodology for the problem analysis developed and applied by the European Commission. After taking a closer look at the availab

疾驰 发表于 2025-3-26 10:28:22

http://reply.papertrans.cn/15/1438/143703/143703_28.png

把…比做 发表于 2025-3-26 13:18:27

http://reply.papertrans.cn/15/1438/143703/143703_29.png

松果 发表于 2025-3-26 18:20:28

http://reply.papertrans.cn/15/1438/143703/143703_30.png
页: 1 2 [3] 4 5
查看完整版本: Titlebook: Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law; Daria Kim Book 2021 The Editor(s) (if applicable) and The Au